Dutch CardioVascular Alliance

What Dutch CardioVascular Alliance does

The Dutch CardioVascular Alliance (DCVA) is a private non-profit network organization founded in 2018 and headquartered in Utrecht, the Netherlands. It functions as a coordinating alliance rather than a product company, uniting 24 partner organizations spanning research funders (ZonMw, NWO, Health~Holland), academic medical centers (NFU representing all 8 UMCs, 4TU for technical universities), professional societies (NVVC, WCN), patient advocates (Harteraad, Stichting Hartekind), industry (VIG), and disease foundations (Nierstichting, Hersenstichting). Its stated ambition is to lower the Dutch cardiovascular disease burden by 25% by 2030, with current patient prevalence of approximately 1.4 million rising to a projected 1.9 million.

DCVA's operational assets include the DCVA Health Data Hub and DCVA Data Catalogue & Request Portal for FAIR cardiovascular data sharing, the Durrer Center Biobank holding over 300,000 samples, and the Netherlands Heart Tissue Bank. It runs the DCVA Leadership Program (15-participant, two-year cohort model) and supports 30+ national consortia across six pillars: Research Policy, Valorization, Implementation, Talent, Data Infrastructure, and Public Affairs & Communication. Recent consortium outputs include the LoDoCo2 trial (which supported FDA approval of Lodoco/colchicine in 2023), the €11M Holland Hybrid Heart soft-robotics artificial heart project, and AI-driven initiatives like CardiacCare@Home and MyDigiTwin.

Commercially, DCVA does not sell products or charge for services. Its operating revenue consists of contributions from its 24 partner organizations and sponsorship funds managed independently by the Stichting Stimuleringsfonds CardioVasculaire Projecten foundation. Its business model is functionally that of a publicly funded research coordination body: aggregating partner contributions, passing through consortium funding, and monetizing impact through translational outputs rather than direct revenue capture. Customer segmentation is bilateral: B2B-style partner organizations serve as funders and collaborators, while Dutch cardiovascular patients constitute the end beneficiary of the alliance's mission.

Name

Dutch CardioVascular Alliance

Legal name

Dutch Cardiovascular Alliance

Website

https://dcvalliance.nl

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

The Dutch CardioVascular Alliance (DCVA) is a Dutch non-profit network organization, founded in 2018, that unites 24 partner organizations across research, academia, healthcare, patient groups, and industry to coordinate cardiovascular research and reduce cardiovascular disease burden by 25% by 2030.

Ownership category

akta.pro rank

Product category

Cardiovascular Research Network Coordination

NAICS

Research and Development in the Physical, Engineering, and Life Sciences (54171)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Global Health Research, Clinical Trials & Product Development Partnerships (PDPs) (HLAJAOAM)

Keywords

• Cardiovascular research consortia
• Health data infrastructure
• Biomedical biobank services
• Public-private partnerships
• Research funding management

Headquarters

HQ city

Utrecht

HQ country

Netherlands

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Partner Contributions & Sponsorship: DCVA is funded through contributions from its 24 partner organizations, including research funders, healthcare organizations, patient groups, and industry partners. The Stichting Stimuleringsfonds CardioVasculaire Projecten independently manages sponsorship funds from companies operating within the cardiovascular domain.
2. Project Funding Allocation: The Stichting Stimuleringsfonds CardioVasculaire Projecten receives, manages, and allocates sponsorship funds to support DCVA objectives including early detection, better use of data, and accelerating translation of scientific research into clinical practice. Funding comes from companies in the cardiovascular domain.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels7 records

Core offering

DCVA is a national network organization that coordinates cardiovascular research, data infrastructure, and collaboration among 24 partner organizations (research funders, academic medical centers, healthcare professional societies, patient associations, and industry) to reduce the cardiovascular disease burden by 25% by 2030. It facilitates 30+ national research consortia, manages dedicated funding through the Stichting Stimuleringsfonds CardioVasculaire Projecten, operates the DCVA Health Data Hub and biobanks (Durrer Center, Netherlands Heart Tissue Bank), and runs the DCVA Leadership Program for talent development.

Product overview

The Dutch CardioVascular Alliance (DCVA) is a network organization, not a traditional product company. It operates as a coordination and facilitation body uniting 24 leading cardiovascular organizations (patients, academia, healthcare professionals, health funds, research funders, and industry) to reduce cardiovascular disease burden by 25% by 2030. The DCVA's offering consists of collaborative infrastructure and programs rather than a unified product portfolio. Key offerings include: the DCVA Leadership Program for talent development; support for over 30 national research consortia (including CardiacCare@Home, Heart4Data, Holland Hybrid Heart, Delta Plan Heart Failure); the Stimuleringsfonds Cardiovasculaire Projecten for funding management; and the DCVA Health Data Hub providing data infrastructure services including the Durrer Center biobank (300,000+ samples) and Netherlands Heart Tissue Bank. The alliance operates through six strategic pillars: Research Policy, Valorization, Implementation, Talent, Data Infrastructure, and Public Affairs & Communication.

Differentiator

Problem solved

Functional benefit

Products and services

• DCVA Leadership Program A two-year leadership development program creating a network of talented people who will become future leaders in cardiovascular health. Each cohort of 15 participants develops competencies in collaboration, communication, leadership, and entrepreneurial skills while working on solutions for current cardiovascular issues. For researchers, healthcare professionals, entrepreneurs, policy advisors, and patients.
• DCVA Consortia Support Facilitation and support for national-scale research collaborations organized in more than 30 consortia, characterized by collaboration of knowledge institutes and public/private organizations focused on specific cardiovascular themes (e.g., CardiacCare@Home, Heart4Data, Holland Hybrid Heart, Delta Plan Heart Failure, Aneurysm-NL, LoDoCo2).
• Stimuleringsfonds Cardiovasculaire Projecten Independent foundation receiving and managing sponsorship funds from companies operating within the cardiovascular domain to support DCVA objectives, enabling investigator and partner initiated projects to be funded in a fair and visible manner with focus on early detection, data use, and translation of research into clinical practice.
• DCVA Health Data Hub Expertise center for cardiovascular health data building sustainable infrastructure for accessing and reusing Electronic Health Record (EHR) and registration data from primary care processes to enhance quality and research. For cardiovascular researchers across Dutch institutions.
• DCVA Catalogue & Request Portal Data catalogue with metadata of all cardiovascular consortium projects funded by DCVA partners, providing an overview of collected data and access procedures for research purposes. Enables FAIR data reuse across the Dutch cardiovascular research community.
• Netherlands Heart Tissue Bank (Nederlandse Hartenbank) Central biobank collecting and storing high-quality cardiac tissue from donors with related clinical data, available for cardiovascular researchers to study pathophysiological mechanisms and improve diagnostics.
• Durrer Center Biobank Facilitates expertise and services to collect, manage, store, archive and share biological samples in cardiovascular research with over 300,000 samples in storage from multi-center studies. For cardiovascular researchers across the Netherlands.
• Delta Plan Heart Failure National project bringing together healthcare professionals, researchers, and patients to focus on the entire heart failure continuum from prevention to palliative care. Coordinated by the Dutch Heart Foundation, Netherlands Heart Institute, and DCVA.

Quantifiable outcome

• LoDoCo2 trial demonstrated 30% reduction in risk of myocardial infarction, stroke, or need for coronary bypass/stent placement with low-dose colchicine in secondary prevention of cardiovascular disease
• +2 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability8 records

Feature4 records

Partnerships

20 partnerships are on record, tiered core and minor.

• Hartstichting (Dutch Heart Foundation)coreStrategic or Co-development PartnerThe Dutch Heart Foundation is the primary founder and a core strategic partner of the DCVA. It plays a pivotal role in both the formation and funding of consortia, setting an example within the network. It coordinates initiatives such as the Delta Plan Heart Failure and has invested in cardiovascular start-ups alongside DCVA.
• Netherlands Heart Institute (NLHI)coreStrategic or Co-development PartnerNLHI is a key academic partner that co-leads the annual DCVA-NLHI Translational Cardiovascular Research Meeting and co-organizes the DCVA-NLHI Congress. It also houses the International Scientific Advisory Board.
• NFU (Nederlandse Federatie van Universitair Medische Centra)coreStrategic or Co-development PartnerNFU represents all eight university medical centers in the Netherlands and contributes academic research capacity to DCVA consortia.
• 4TUcoreStrategic or Co-development Partner4TU represents the four technical universities in the Netherlands (TU Delft, TU Eindhoven, University of Twente, Wageningen UR) contributing engineering and technology expertise to cardiovascular research.
• ZonMwcoreStrategic or Co-development PartnerZonMw is the Dutch health research funding organization that co-funds DCVA consortia including LoDoCo2, BENEFIT, and others through its Good Use of Medicines program.
• NWO (Nederlandse Organisatie voor Wetenschappelijk Onderzoek)coreStrategic or Co-development PartnerNWO is the Dutch Research Council providing research funding and supporting DCVA consortia including CardiacCare@Home through NWO Perspective TTW and the Big Data & Health Program.
• Health~HollandcoreStrategic or Co-development PartnerHealth~Holland is the Dutch life sciences & health research cluster that co-funds public-private partnerships within the DCVA network.
• NVVC (Nederlandse Vereniging voor Cardiologie)coreStrategic or Co-development PartnerNVVC is the Dutch Society of Cardiology, representing cardiologists who participate in DCVA consortia and the annual congress. NVVC Connect facilitates regional cardiac care networks.
• WCN (Werkgroep Cardiologie Nederland)coreStrategic or Co-development PartnerWCN is a non-academic network of cardiologists that fully ran the LoDoCo2 clinical trial, demonstrating a unique public-private research model for cardiovascular drug repurposing.
• Netherlands Heart Registration (NHR)coreStrategic or Co-development PartnerNHR provides registry infrastructure for heart failure and atrial fibrillation data, supporting the Heart4Data consortium's goal of registry-based cardiovascular research.
• KNAW (Koninklijke Nederlandse Akademie van Wetenschappen)coreStrategic or Co-development PartnerKNAW is the Royal Netherlands Academy of Arts and Sciences, contributing academic prestige and oversight to the DCVA network.
• HarteraadcoreStrategic or Co-development PartnerHarteraad is the Dutch patient association for people with heart disease, representing patient perspectives in DCVA consortia and collaborating on the online patient platform.
• VIG (Vereniging Innovatieve Geneesmiddelen)coreStrategic or Co-development PartnerVIG represents innovative medicines companies in the Netherlands, contributing industry perspective and potential co-development partnerships for DCVA research.
• Nierstichting (Kidney Foundation)coreStrategic or Co-development PartnerThe Kidney Foundation contributes to DCVA as cardiovascular and kidney diseases are closely linked, participating in consortia such as RECONNEXT that study the heart-kidney connection.
• Hersenstichting (Brain Foundation)coreStrategic or Co-development PartnerThe Brain Foundation joined DCVA as a new partner in 2025, recognizing the interconnection between cardiovascular and neurological diseases including stroke.
• NVNG (Nederlandse Vereniging voor Neurochirurgie)coreStrategic or Co-development PartnerNVNG joined DCVA as a new partner in 2025, bringing neurosurgical expertise particularly relevant to aneurysm research and stroke care.
• RegMed XBcoreStrategic or Co-development PartnerRegMed XB collaborates with DCVA on the Valorization Community & Network Events focused on public-private partnerships in chronic diseases, including cardiovascular conditions.
• Social Impact FactoryminorStrategic or Co-development PartnerSocial Impact Factory in Utrecht hosts DCVA-RegMed XB Valorization Community & Network Events, providing the venue for networking between academic researchers, startups, and industry partners.
• Amolf (Soft Robotic Matter Group)coreStrategic or Co-development PartnerAmolf's Soft Robotic Matter group, led by Bas Overvelde, collaborates with Erasmus MC on the Holland Hybrid Heart project, contributing soft robotics expertise for developing an artificial heart.
• Young@HeartminorStrategic or Co-development PartnerYoung@Heart supports young researchers in the cardiovascular field and co-sponsors the DCVA-NLHI Translational Cardiovascular Research Meeting, alongside being part of the Talent pillar.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• American Heart Association: Largest US cardiovascular organization funding research, advocacy and clinical guidelines. Comparable in mission (reducing CV disease burden) and breadth of activities (research funding, data, advocacy, training) but at much larger scale and US-centric.
• National Heart, Lung, and Blood Institute (NHLBI): US federal institute within NIH driving cardiovascular research funding, large-scale cohort studies and clinical trials networks. Comparable to DCVA as a national-level coordinator of cardiovascular research infrastructure and consortia, though government-funded vs DCVA's public-private partnership model.
• British Heart Foundation: UK's largest cardiovascular research charity funding universities, hospitals and research programs; overlaps with DCVA's mission of cardiovascular burden reduction and research funding across the UK, though it operates more as a funder than a coordination network.

Regional players

• INSERM: French national institute for health and medical research coordinating biomedical research across France. Comparable as a national-level health R&D coordinator, though broader than cardiovascular and primarily government-funded; a relevant comparison for European national alliance models.
• Italian IRCCS Cardiovascular Network: Network of Italian scientific institutes for research and healthcare (IRCCS) focused on cardiovascular disease, with national coordination of clinical and translational research. Comparable to DCVA in national-level cardiovascular network scope within a different European country.

Others

• RegMed XB: Dutch public-private partnership in regenerative medicine that co-hosts DCVA Valorization events. Comparable as a Dutch public-private partnership model coordinating R&D across academia, industry and government in a specific disease area, with shared governance and funding flows.
• European Society of Cardiology (ESC): Pan-European professional society for cardiology with guidelines, registries and congress infrastructure. Comparable to DCVA's stakeholder coordination across cardiologists and researchers but with a continental scope and society rather than alliance structure.
• ZonMw: Dutch health research funding organization that co-funds DCVA consortia (LoDoCo2, BENEFIT) and is a core strategic partner. Comparable as an enabler/funding mechanism rather than direct competitor; relevant for understanding the Dutch CV research funding landscape.

Direct peers

• Fondation Leducq: International non-profit foundation funding collaborative cardiovascular and stroke research networks across multiple countries. Comparable to DCVA's mission-driven, multi-institution research coordination model, focused on transatlantic cardiovascular collaboration.
• German Centre for Cardiovascular Research (DZHK): DZHK is Germany's national cardiovascular research network integrating university hospitals, research institutes and partners across basic, translational and clinical research. It is DCVA's closest structural analogue in another European market with a multi-partner alliance model targeting cardiovascular disease burden reduction.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/dutch-cardiovascular-alliance
• Instagraminstagram.com/dcvalliance
• Xx.com/dcvalliance

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dutch CardioVascular Alliance